CANCERS BRONCHIQUES NON A PETITES CELLULES AU STADE AVANCE |
|
|
référence |
chimiothérapie |
n |
(st IV) |
% RO |
p |
SM |
p |
|
Gridelli, 2007 (1) |
I. Pemetrexed 500 |
44 |
82 % |
4,5 % |
|
|
NS |
|
II.
Pemetrexed 500 2x puis
gemcitabine 2x (séquentiel) |
43 |
81 % |
11,6 % |
|
|||
|
Scagliotti, 2008 (2) I |
I. cisplatine (75) + gemcitabine |
863 |
76 % |
? |
|
|
NS |
|
II. cisplatine (75) + pemetrexed |
862 |
76 % |
? |
|
|||
|
Gronberg, 2009 (3) I |
I. pemetrexed 500 + Carbo AUC 5 |
225 |
71 % |
|
|
|
NS |
|
II. gemcitabine 2 x 1 + Carbo AUC
5 |
221 |
72 % |
|
|
Références
(1) Gridelli C, Kaukel E, Gregorc V, Migliorino MR, Muller TR, Manegold C, et al. Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial. J Thorac Oncol 2007 Mar;2(3):221-9.
(2) Scagliotti GV, Parikh P, von PJ, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008 Jul 20;26(21):3543-51.
(3) Gronberg BH, Bremnes RM, Flotten O, Amundsen T, Brunsvig PF, Hjelde HH, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009 Jul 1;27(19):3217-24.